California Company Conference Letter to Leadership Regarding Orphan Drug Tax Credit – December 2017
December 11, 2017
The Honorable Kevin McCarthy
House Majority Leader
H-107, U.S. Capitol
Washington, D.C. 20515
Dear Majority Leader McCarthy,
As leading California companies that are focused on developing treatments and cures for patients afflicted with rare diseases, we write to let you know of our strong support for the Orphan Drug Tax Credit (ODTC). As you and the House conferees work to align the House- and Senate-passed versions of the Tax Cuts and Jobs Act, we urge you to ensure this meaningful incentive for rare disease therapy innovation is protected and preserved in the final bill.
As you may know, a rare disease or condition is defined as one which affects 200,000 or fewer persons in the United States. An orphan drug is a therapy treating such a rare disease. The National Institutes of Health recognizes between 6,000 and 7,000 rare diseases and medical disorders that affect more than 30 million Americans (one in 10).